Detail akcie NexImmune Rg online

Business Summary: NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Neximmune Inc revenues was not reported. Net loss decreased 68% to $3.1M. Lower net loss reflects Research and development - Balancing val decrease of 89% to $669K (expense), General and administrative - Balancing decrease of 44% to $1.7M (expense), Stock-based Compensation in SGA decrease of 53% to $273K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$9.17 to -$2.46.